drugset / Trial / NCT02045693
Drug Interaction & Methadone & Buprenorphine
Non-randomizedParallel-groupOpen-label
Summary
The purpose of this study is to assess the effects of steady state DCV/ASV/BMS-791325 fixed dose combination (FDC) + 75mg BMS-791325 on the Pharmacokinetics (PK) of Methadone in subjects with the stable dose of Methadone and on the PK of Buprenorphine in subjects with the stable dose of Buprenorphine.
Timeline
- Start
- 2014-02
- Primary completion
- 2014-04
- Completion
- 2014-04
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Buprenorphine | Other / unclassified | 8 mg | Oral |
| Comparator | Buprenorphine | Other / unclassified | 24 mg | Oral |
| Subject | Methadone | Other / unclassified | 40 mg | Oral |
| Subject | Methadone | Other / unclassified | 120 mg | Oral |
| Background | Asunaprevir | Small molecule | 200 mg | Oral |
| Background | Beclabuvir | Small molecule | 75 mg | Oral |
| Background | Daclatasvir | Small molecule | 30 mg | Oral |
| Comparator | Naloxone | Small molecule | 2 mg | Oral |
| Comparator | Naloxone | Small molecule | 6 mg | Oral |